2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea

DOI PDF Web Site Web Site PubMed 被引用文献2件 オープンアクセス
  • Mee Kyoung Kim
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Seung-Hyun Ko
    Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
  • Bo-Yeon Kim
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.
  • Eun Seok Kang
    Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Junghyun Noh
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.
  • Soo-Kyung Kim
    Division of Endocrinology and Metabolism, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
  • Seok-O Park
    Gwangmyeong Sungae Hospital, Gwangmyeong, Korea.
  • Kyu Yeon Hur
    Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Suk Chon
    Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea.
  • Min Kyong Moon
    Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
  • Nan-Hee Kim
    Department of Internal Medicine, Korea University College of Medicine, Ansan, Korea.
  • Sang Yong Kim
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University College of Medicine, Gwangju, Korea.
  • Sang Youl Rhee
    Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea.
  • Kang-Woo Lee
    Sejong St. Mary's Diabetes and Endocrine Clinic, Sejong, Korea.
  • Jae Hyeon Kim
    Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Eun-Jung Rhee
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • SungWan Chun
    Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea.
  • Sung Hoon Yu
    Department of Endocrinology and Metabolism, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
  • Dae Jung Kim
    Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea.
  • Hyuk-Sang Kwon
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Kyong Soo Park
    Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea.

書誌事項

公開日
2019
権利情報
  • http://creativecommons.org/licenses/by-nc/4.0/
DOI
  • 10.4093/dmj.2019.0137
公開者
Korean Diabetes Association

この論文をさがす

説明

The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the 6th Clinical Practice Guidelines in 2019. Targets of glycemic, blood pressure, and lipid control in type 2 diabetes mellitus (T2DM) were updated. The obese and overweight population is increasing steadily in Korea, and half of the Koreans with diabetes are obese. Evidence-based recommendations for weight-loss therapy for obesity management as treatment for hyperglycemia in T2DM were provided. In addition, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations.

収録刊行物

被引用文献 (2)*注記

もっと見る

キーワード

問題の指摘

ページトップへ